ライフサイエンスコーパス: cardiac death

1 milies (230 relatives, 80 unexplained sudden cardiac death).

2 is an uncommon but important cause of sudden cardiac death.

3 malignant ventricular arrhythmias and sudden cardiac death.

4 on, life-threatening arrhythmias, and sudden cardiac death.

5 Tc, >480 ms) with a family history of sudden cardiac death.

6 lar Arrhythmias and the Prevention of Sudden Cardiac Death.

7 increase the risk of arrhythmias and sudden cardiac death.

8 cular walls and is a leading cause of sudden cardiac death.

9 and is associated with a high risk of sudden cardiac death.

10 urgitation, and it is associated with sudden cardiac death.

11 on, which can result in revascularisation or cardiac death.

12 myocardial fibrofatty replacement and sudden cardiac death.

13 ion, which poses an increased risk of sudden cardiac death.

14 ointes, and aborted cardiac arrest or sudden cardiac death.

15 from ventricular tachycardia (VT) and sudden cardiac death.

16 sease, cardiomyopathy, arrhythmia, or sudden cardiac death.

17 rdium, resulting in heart failure and sudden cardiac death.

18 significant ventricular arrhythmia or sudden cardiac death.

19 eading to acute coronary syndrome and sudden cardiac death.

20 e focused on identifying high-risk of sudden cardiac death.

21 She had no family history of sudden cardiac death.

22 d for coronary revascularization, stroke, or cardiac death.

23 na, need for coronary revascularization, and cardiac death.

24 at the greatest risk of sudden and nonsudden cardiac death.

25 , which in turn predisposes to VA and sudden cardiac death.

26 ypertrophy are major risk factors for sudden cardiac death.

27 iated with delayed repolarization and sudden cardiac death.

28 indicated for prevention of secondary sudden cardiac death.

29 ions lead to heart attack, stroke, or sudden cardiac death.

30 truction, and risk stratification for sudden cardiac death.

31 oal of treatment is the prevention of sudden cardiac death.

32 arget vessel myocardial infarction, TLR, and cardiac death.

33 heart rhythm disorder associated with sudden cardiac death.

34 ading to ventricular fibrillation and sudden cardiac death.

35 rillators, which have no impact on nonsudden cardiac death.

36 d syncope, aborted cardiac arrest, or sudden cardiac death.

37 r tachycardia or long QT syndrome and sudden cardiac death.

38 tachycardia (VT) is a major cause of sudden cardiac death.

39 myocardial injury, cardiomyopathy, and even cardiac death.

40 ardioverter-defibrillator shocks, and sudden cardiac death.

41 ive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death.

42 inical conditions and with a greater risk of cardiac death.

43 nd hibernation can inform the risk of sudden cardiac death.

44 nic shock, arrest, complete heart block, and cardiac death.

45 iated with poor cardiac prognosis and sudden cardiac death.

46 epilepsy, schizophrenia, cancer, and sudden cardiac death.

47 attern of ventricular tachyarrhythmia/sudden cardiac death.

48 ng the risk of Torsade de pointes and sudden cardiac death.

49 ion, late (>180 days) revascularization, and cardiac death.

50 myocardial ischemia, arrhythmia, and sudden cardiac death.

51 buting to ventricular arrhythmias and sudden cardiac death.

52 e type 1, which can cause syncope and sudden cardiac death.

53 risk for ventricular fibrillation and sudden cardiac death.

54 ge of symptoms and may even result in sudden cardiac death.

55 vice implantation, severe heart failure, and cardiac death.

56 lt in serious consequences, including sudden cardiac death.

57 enesis of ventricular arrhythmias and sudden cardiac death.

58 heart failure and reduce the risk for sudden cardiac death.

59 5% it is associated with high risk of sudden cardiac death.

60 and a low-intermediate 5-year risk of sudden cardiac death.

61 lity and a 0.003% (0.001-0.006) reduction in cardiac deaths.

62 cular tachycardia >240 bpm) and 36 nonsudden cardiac deaths.

63 .15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths.

64 There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference

65 2 months (range 1 to 28 months), there was 1 cardiac death, 1 noncardiac death, no other mortality, a

66 edian: 23 months, Q1-Q3: 11 to 28 months), 1 cardiac death, 12 strokes, and 42 HF episodes occurred.

67 Risks of cardiac death (2.0% versus 2.1%; HR, 1.03; 95% CI, 0.47-

68 mon cause of cardiovascular death was sudden cardiac death (20.1%); while myocardial infarction (5.2%

69 Rates of cardiac death (3.9% versus 3.8%; P=0.88), target vessel

70 occurred in 9.4% of patients (including 2.9% cardiac death, 3.1% MI, and 5.1% ID-TLR).

71 ll-cause death (10.4% vs. 8.7%; p = 0.0008), cardiac death (4.9% vs. 4.0%; p = 0.003) and ID-TLR (10.

72 ifferences were noted in the rates of 1-year cardiac death (44 [4.0%] for the bivalirudin group vs 48

73 ed highly prevalent family history of sudden cardiac death (51%) and cardiomyopathy (72%) among index

74 Correspondingly, they considered cardiac death a better indicator of death and were more

75 y normal heart carries a low risk for sudden cardiac death; accordingly, there is typically no indica

76 al was associated with higher risk of sudden cardiac death (adjusted hazard ratio, 1.18; 95% confiden

77 ase progression and one patient died (sudden cardiac death after 17 months of ibrutinib maintenance,

78 aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to 11.2) over a m

79 design to compare the 1-year risk of sudden cardiac death among hemodialysis patients initiating SSR

80 ucing risk of all-cause mortality and sudden cardiac death among patients with an EF </=35% at baseli

81 ad a 4-fold higher risk of cardiac or sudden cardiac death and a 2-fold higher risk of any-cause deat

82 omyopathy (DCM) is a leading cause of sudden cardiac death and a major indicator for heart transplant

83 als, can acutely increase the risk of sudden cardiac death and acute myocardial infarction in suscept

84 c conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 1

85 y with long-term follow-up, (aborted) sudden cardiac death and mortality rates were found to be simil

86 for superiority), as was the primary safety (cardiac death and myocardial infarction) composite (9.3%

87 ion revascularization) and safety (composite cardiac death and myocardial infarction) end points were

88 Modes of death were divided into sudden cardiac death and nonsudden death and compared between p

89 prediction and prevention of SCA and sudden cardiac death and provides justification for a research

90 ing parametric risk models to predict sudden cardiac death and pump failure in the DCM population.

91 ch carries significant mortality from sudden cardiac death and pump failure.

92 For this review, we analyzed data on sudden cardiac death and SCA available from population studies

93 the incidence of subsequent heart failure or cardiac deaths) and increased health-care costs when the

94 nd nonfatal myocardial infarction and sudden cardiac death), and harms.

95 everity expression, high-incidence of sudden cardiac death, and absence of skeletal myopathy or condu

96 use mortality, heart transplantation, sudden cardiac death, and appropriate implantable cardioverter

97 Heart failure, cardiac death, and cardiac dysfunction were infrequent i

98 implantation on all-cause mortality, sudden cardiac death, and cardiovascular death.

99 required due to an elevated risk for sudden cardiac death, and catheter ablation can be used as adju

100 cardiovascular event (myocardial infarction, cardiac death, and fatal or non-fatal stroke) using the

101 cipient age, older donor age, donation after cardiac death, and longer cold ischemia.

102 PCI prevents death, cardiac death, and MI in patients with unstable CAD.

103 ycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major

104 s known as the stroke-heart syndrome, sudden cardiac death, and Takotsubo syndrome, among other neuro

105 oward brain death are compared with those of cardiac death; and (3) the extent to which brain death p

106 22 patients had hard cardiac events (sudden cardiac death, appropriate implantable cardioverter-defi

107 A clinical combined endpoint of cardiac death, appropriate implantable cardioverter-defi

108 to 8 years), the combined endpoint of sudden cardiac death, appropriate implantable cardioverter-defi

109 ibrillators for primary prevention of sudden cardiac death are less likely to experience sustained ve

110 sustained ventricular arrhythmias and sudden cardiac death are lower in women than in men.

111 ustained ventricular arrhythmias, and sudden cardiac death are recognized.

112 including pulmonary hypertension and sudden cardiac death, are significantly higher for people livin

113 compared with other etiologies, with sudden cardiac death as an important mode of death.

114 ral artery disease, heart failure and sudden cardiac death, as well as how to select available therap

115 on an estimate of a patient's risk of sudden cardiac death, as well as their preferences and values.

116 entile, the risk of myocardial infarction or cardiac death at 12 months was 77% lower in those <5 ng/

117 condary outcome was myocardial infarction or cardiac death at 12 months, with risk modeled using logi

118 Cardiac death at 30 days (2.8% versus 0.8%; P=0.03) and

119 r severe aortic regurgitation at 30 days and cardiac death at 30 days and 1 year.

120 farction, or type 1 myocardial infarction or cardiac death at 30 days.

121 nfarction or type 1 myocardial infarction or cardiac death at 30 days.

122 primary outcome was myocardial infarction or cardiac death at 30 days.

123 There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a

124 -defibrillator firings and arrhythmic sudden cardiac death) at 5 years of follow-up.

125 families who experienced unexplained sudden cardiac death before 45 years of age were included from

126 syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6-269.1; P<0.0

127 onally been used as a risk marker for sudden cardiac death, but has performed poorly in trials.

128 t failure are at an increased risk of sudden cardiac death, but more discriminating tools are needed

129 on channel, have been associated with sudden cardiac death, but only a subset of these variants have

130 Catastrophic arrhythmias and sudden cardiac death can occur with even a small imbalance betw

131 pre-dispose to 4 important causes of sudden cardiac death: cardiomyopathy, coronary artery disease,

132 ase-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from 106,09

133 Among the 1,200 sudden cardiac death cases and controls, the authors identified

134 alence of rare pathogenic variants in sudden cardiac death cases versus controls, and the prevalence

135 ividuals, all of whom had experienced sudden cardiac death-corresponding to a pathogenic variant prev

136 P < 0.0001), more frequently donation after cardiac death (DCD) (18% vs 7%, P < 0.001), and having a

137 Increasingly, donation after cardiac death (DCD) donors are used in view of the organ

138 jury (IRI) of renal allografts donated after cardiac death (DCD) in a porcine animal model of transpl

139 stablished complication after donation after cardiac death (DCD) kidney transplants, but the impact o

140 Outcomes of both donation after cardiac death (DCD) liver and kidney transplants are imp

141 ediately, whereas organs from donation after cardiac death (DCD) or acute kidney injury (AKI) donors

142 time (HT), in the context of donation after cardiac death (DCD) procurement, impacts short- and long

143 from donors with 30 minutes (donation after cardiac death [DCD]30'), 70 minutes (DCD70'), and 120 mi

144 s from older (age >=50 years) donation after cardiac death (DCD50) donors are less likely to be trans

145 Noncardiac and any cardiac deaths did not differ significantly by treatment

146 positive donors, livers from donation after cardiac death donors, livers with >30% steatosis, and li

147 ection fraction for the prediction of sudden cardiac death events.

148 For sudden cardiac death, FHSD, nsVT, and obstruction showed signif

149 tio, 0.45 [95% CI, 0.29-0.69], P=0.0002) and cardiac death (hazard ratio, 0.38 [95% CI, 0.18-0.74], P

150 f upright CSR independently predicted 8-year cardiac death (hazard ratio: 2.39; 95% CI: 1.08 to 5.29;

151 ome patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrillation.

152 alovirus seropositive status, donation after cardiac death, hepatitis B and C seropositive status, ci

153 primary efficacy endpoint was a composite of cardiac death; hospital admission for a cardiac event; r

154 ferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hospitalization, and

155 idence intervals (CI), 1.02-1.09]; P=0.001), cardiac death (HR, 1.10 [95% CI, 1.05-1.17]; P<0.001), a

156 HR: 0.91; 95% CI: 0.75 to 1.09; p = 0.30) or cardiac death (HR: 0.97; 95% CI: 0.73 to 1.29; p = 0.85)

157 receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in only 0

158 tly contributes to the high rates of LVH and cardiac death in CKD.

159 syndrome (LQTS) is a leading cause of sudden cardiac death in early life and has been implicated in ~

160 sus 17%, P=0.020), and higher rate of sudden cardiac death in first degree relatives<age 30 (4.5% ver

161 es without children and families with sudden cardiac death in first-degree relatives <40 years.

162 the susceptibility to arrhythmias and sudden cardiac death in HD patients.

163 Utilising the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry (11 A

164 alysis examined data collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which r

165 The SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) randomized 2,521 p

166 g ICDs as part of the SCD-HeFT trial (Sudden Cardiac Death in Heart Failure Trial).

167 r (ICD) use for primary prevention of sudden cardiac death in heart failure with reduced ejection fra

168 ally and patients at risk for SCA and sudden cardiac death in particular is limited by the diversity

169 er-defibrillators are used to prevent sudden cardiac death in patients with cardiac sarcoidosis.

170 D) is the standard therapy to prevent sudden cardiac death in patients with coronary artery disease a

171 ged QT intervals, cardiomyopathy, and sudden cardiac death in several pedigrees.

172 on between these 'maladaptations' and sudden cardiac death in the general population raises the quest

173 reased and so far unexplained risk of sudden cardiac death in the hemodialysis patient population.

174 A significant proportion of sudden cardiac death in the young (<=35 years) events may be pr

175 will outline the underlying causes of sudden cardiac death in the young and outline our universal app

176 y (CA) is the second leading cause of sudden cardiac death in young athletes.

177 ses are often the underlying cause of sudden cardiac death in young individuals and result from mutat

178 thmic events (LAE) (cardiac arrest or sudden cardiac death) in SQTS patients.

179 Sudden cardiac death is a complication of a number of cardiovas

180 Sudden cardiac death is defined as a death occurring usually wi

181 Sudden cardiac death is responsible for half of all deaths from

182 dividuals aged <35 years, unexplained sudden cardiac death is the most common presentation.

183 QT syndrome has been associated with sudden cardiac death likely caused by early afterdepolarization

184 lesion-related major adverse cardiac events (cardiac death, MI, unstable angina, or progressive angin

185 sex and major adverse cardiac events (MACE) (cardiac death, myocardial infarction [MI], or ischemia-d

186 Very-late MACE (a composite of cardiac death, myocardial infarction [MI], or ischemia-d

187 ular events, was defined as the composite of cardiac death, myocardial infarction not related to any

188 ac event (MACE) assessed as the composite of cardiac death, myocardial infarction, and target vessel

189 Major adverse cardiac events (MACE) included cardiac death, myocardial infarction, definite or probab

190 cardiac events, defined as the composite of cardiac death, myocardial infarction, or definite-probab

191 cardiovascular events (MACE; a composite of cardiac death, myocardial infarction, or ischemia-driven

192 e primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosi

193 diac events were defined as the composite of cardiac death, myocardial infarction, or stent thrombosi

194 cardiovascular events (MACE), a composite of cardiac death, myocardial infarction, or target vessel r

195 as in-hospital major adverse cardiac events (cardiac death, myocardial infarction, or target vessel r

196 om from major adverse cardiovascular events (cardiac death, myocardial infarction, or target vessel r

197 Major adverse cardiac events (cardiac death, nonfatal MI, unplanned hospitalization fo

198 the combined primary end point (composite of cardiac death, nonfatal myocardial infarction, and strok

199 Cardiac death occurred in 10 (1.3%) versus 10 patients (

200 Cardiac death occurred in 18 patients in the scaffold gr

201 ce and gastrointestinal symptoms; one sudden cardiac death occurred in the SEP-363856 group.

202 erquartile range [IQR]: 17 to 36 months), 50 cardiac deaths occurred.

203 Sudden cardiac death occurs in ~220,000 U.S. adults annually, t

204 -0.98; P=0.004) and family history of sudden cardiac death (odds ratio, 3.5; 95% confidence interval,

205 LTVTA was defined as (1) sudden cardiac death or (2) implantable cardioverter defibrilla

206 d a secondary arrhythmic end point of sudden cardiac death or appropriate implantable cardioverter-de

207 The most frequent SCEs were cardiac death or arrest, heart failure, arrhythmias, and

208 SCEs included cardiac death or arrest, ventricular arrhythmias, conges

209 ion for heart failure, 8% experienced sudden cardiac death or equivalent, 4% required heart transplan

210 ass, and 6 patients (27%) experienced sudden cardiac death or equivalent.

211 I, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the

212 The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12

213 itioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 1

214 The primary analysis of cardiac death or myocardial infarction between 1 month a

215 revascularization, including a reduction in cardiac death or myocardial infarction, as well as costs

216 The primary outcome was the composite of cardiac death or myocardial infarction.

217 YL4 expression did not associate with sudden cardiac death or other cardiomyopathies.

218 jor arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asymptomat

219 - Increased Risk designated, deceased after cardiac death, or deceased after cerebrovascular acciden

220 a history of ventricular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator

221 er, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adu

222 eart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athlet

223 n heart failure with primary focus on sudden cardiac death prevention and cardiac resynchronization,

224 lator (ICD) is safe and effective for sudden cardiac death prevention.

225 tors (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with

226 ereas for patients >70 years old, the sudden cardiac death rate was 1.6 (95% CI, 0.8-3.2) and nonsudd

227 For patients </=70 years old, the sudden cardiac death rate was 1.8 (95% CI, 1.3-2.5) and nonsudd

228 ADIRs included cardiac death, reinfarction, and definite stent thrombos

229 Major adverse cardiac events consisting of cardiac death, reinfarction, and new congestive heart fa

230 rs' preserved fluid from DCD (donation after cardiac death) renal transplantation and four isolates i

231 yanotic congenital heart disease, and sudden cardiac death represents an important mode of death in t

232 emerging factors to be considered in sudden cardiac death risk stratification.

233 In unstable CAD, PCI also reduced cardiac death (RR, 0.69 [95% CI, 0.53-0.90]; P=0.007) an

234 ce mortality (RR, 0.98 [95% CI, 0.87-1.11]), cardiac death (RR, 0.89 [95% CI, 0.71-1.12]; P=0.33), or

235 t failure (HF) have increased risk of sudden cardiac death (SCD) and death from progressive pump fail

236 ent progress in profiling of risk for sudden cardiac death (SCD) and prevention and intervention of c

237 Sudden cardiac arrest and sudden cardiac death (SCD) are terms often used interchangeably

238 ardiomyopathy is the leading cause of sudden cardiac death (SCD) in children and young adults.

239 a higher incidence of out-of-hospital sudden cardiac death (SCD) in comparison with whites.

240 sical activity (LTPA) and the risk of sudden cardiac death (SCD) in coronary artery disease patients

241 The risk of sudden cardiac death (SCD) in patients with heart failure after

242 Sudden cardiac death (SCD) in the young is devastating.

243 yopathy for the primary prevention of sudden cardiac death (SCD) in those with a left ventricular eje

244 HCM) is considered a leading cause of sudden cardiac death (SCD) in younger people.

245 Sudden cardiac death (SCD) is a major cause of mortality in adu

246 The risk of sudden cardiac death (SCD) is high early after myocardial infar

247 Sudden cardiac death (SCD) is the leading cause of mortality in

248 Sudden cardiac death (SCD) is the most devastating manifestatio

249 Conventional definitions of sudden cardiac death (SCD) presume cardiac cause.

250 ricular arrhythmias, that can lead to sudden cardiac death (SCD) within minutes.

251 disease carries an elevated risk for sudden cardiac death (SCD), and implantable cardioverter-defibr

252 is are reported to be at high risk of sudden cardiac death (SCD), and to date, no therapy has been sh

253 rhythmia, which is a leading cause of sudden cardiac death (SCD).

254 replacement and an increased risk of sudden cardiac death (SCD).

255 associated with an increased risk of sudden cardiac death (SCD).

256 of the QT interval is associated with sudden cardiac death (SCD).

257 rotein leads to an increased risk for sudden cardiac death (SCD).

258 with ventricular arrhythmias (VA) and sudden cardiac death (SCD).

259 ous phenotype, with increased risk of sudden cardiac death (SCD).

260 The majority of sudden cardiac deaths (SCDs) occur in low-risk populations ofte

261 Ventricular tachyarrhythmias and sudden cardiac death show a circadian pattern of occurrence in

262 between baseline WBC and MACE (composite of cardiac death, stent thrombosis, spontaneous myocardial

263 endpoint was a composite adverse outcome of cardiac death, subsequent HF or stroke, subsequent HF wa

264 vascularization (p < 0.001 for all-cause and cardiac death), such that patients with greater ischemia

265 ce implantation (DHF/HTx/VAD); and 3) sudden cardiac death/sustained ventricular tachycardia/ventricu

266 noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI

267 nt was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and

268 int was target lesion failure-a composite of cardiac death, target vessel myocardial infarction, and

269 Cumulative incidences of cardiac death, target vessel myocardial infarction, and

270 osite end point, defined as the composite of cardiac death, target vessel myocardial infarction, or c

271 noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction, or i

272 (TLF; device-oriented composite end point of cardiac death, target vessel myocardial infarction, or i

273 vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or t

274 dpoint was randomized target lesion failure (cardiac death, target vessel-related MI, or clinically d

275 The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarcti

276 Target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarcti

277 point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarcti

278 zation [ID-TLR]), and target lesion failure (cardiac death, target-vessel MI, or ID-TLR) were assesse

279 ison of a device-oriented composite endpoint-cardiac death, target-vessel myocardial infarction, or c

280 oint of target-lesion failure was defined as cardiac death, target-vessel myocardial infarction, or t

281 nt was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or t

282 risk of subsequent myocardial infarction or cardiac death than those with normal renal function (24%

283 portant subset of adults experiencing sudden cardiac death; these variants are present in ~1% of asym

284 Experience with uncontrolled donors after cardiac death (uDCD), that is, donors with an unexpected

285 Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator implant

286 a low- or intermediate 5-year risk of sudden cardiac death underwent cardiac magnetic resonance imagi

287 was a composite of prospectively adjudicated cardiac death, vessel-related myocardial infarction, ves

288 In contrast, nonsudden cardiac death was associated with a higher resting heart

289 At follow-up, cardiac death was considered as the endpoint.

290 Risk of cardiac death was similar between the 2 groups.

291 Nonsudden cardiac death was treated as a competing event.

292 rs (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago and en

293 Subsequent type 1 myocardial infarction and cardiac death were reported at 1 year.

294 Overall, 181 cardiac deaths were observed, which was 3.4 times that e

295 as stroke, myocardial infarction, or sudden cardiac death, were assessed prospectively over a 10-yea

296 ry low values before they suffer from sudden cardiac death with an unexplained high incidence.

297 After sudden cardiac death with negative autopsy, clinical screening

298 primary outcome of myocardial infarction or cardiac death within 30 days.

299 hose at low risk of myocardial infarction or cardiac death within 30 days.

300 le organs, local cost levels, donation after cardiac death, year, and Standardized Donor Rate Ratio.